Paudel et al. [52] observed that single-cell-derived subclones of the SKMEL5 melanoma cell line, which carries a BRAF mutation, exhibit heterogeneity in their short-term response to the BRAF inhibitor PLX4720 (Fig 6A; also see Figs 2A and 3A in Paudel et al. [52]). The gene discussed is BRAF; the disease is melanoma.